Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.
The Autoimmune Protocol (AIP) diet is an elimination diet designed to help reduce inflammation, manage symptoms and improve ...
A device used in South Jersey is a game-changer for people with inflammatory bowel disease as an alternative to invasive ...
"It really opened my eyes that we really aren't alone," Chloee Rae said about the impact of her music video produced by the ...
Crohn's disease, a type of chronic inflammatory bowel disease (IBD), often causes scar-like tissue to build up in the ...
We recently published a list of the Jim Cramer Just Discussed These 13 Stocks. In this article, we are going to take a look ...
Teva and Sanofi said last year they would collaborate on developing a treatment for inflammatory bowel disease (IBD), hoping ...
Teva and Sanofi report breakthrough results for duvakitug, showing strong efficacy in IBD. Learn how this TL1A drug could ...
The FDA has approved Celltrion’s Stelara biosimilar Steqeyma (CT-P43), for adult and pediatric patients with plaque psoriasis ...
The companies said Tuesday that patients with ulcerative colitis who were treated with duvakitug achieved a higher rate of clinical remission compared with a placebo group. A group of patients with ...
Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...